{"filing":{"accession_number":"0001193125-26-354096","cik":"0000064803","ticker":"CVS","company_name":"CVS HEALTH Corp","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-13","primary_document":"d129035d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/64803/000119312526354096/d129035d8k.htm"},"events":[{"id":28283,"run_id":25860,"accession_number":"0001193125-26-354096","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"CVS Health appointed Teresa Heitsenrether to its board of directors effective November 18, 2026. Heitsenrether is a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience, bringing expertise in data, analytics, and technology transformation to the company's board during a strategic transition period.","company_name":"CVS HEALTH Corp","ticker":"CVS","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30173,"accession_number":"0001193125-26-354096","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two board-level events: the resignation of Larry M. Robbins (effective August 13, 2026) and the appointment of Teresa Heitsenrether (effective November 18, 2026). While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure and the press release is the appointment of Heitsenrether, a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience. The appointment is material to investors as it reflects board composition changes and brings significant expertise in data, analytics, and technology transformation to CVS Health's leadership during a strategic transition period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:22:09.235289+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30174,"accession_number":"0001193125-26-354096","item_number":"7.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces both a board appointment (Teresa Heitsenrether effective November 18, 2026) and a board departure (Larry Robbins, effective August 13, 2026). While the taxonomy includes separate categories for exec_appointment and exec_departure, this filing centers on board composition changes rather than officer/executive management roles. The appointment of a director with significant technology and data analytics expertise to a major healthcare company's board is material to investors assessing governance and strategic direction, but the event is most accurately classified as governance_other since it involves simultaneous appointment and departure at the board level rather than a single executive officer transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:22:09.235289+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30173,"accession_number":"0001193125-26-354096","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two board-level events: the resignation of Larry M. Robbins (effective August 13, 2026) and the appointment of Teresa Heitsenrether (effective November 18, 2026). While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure and the press release is the appointment of Heitsenrether, a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience. The appointment is material to investors as it reflects board composition changes and brings significant expertise in data, analytics, and technology transformation to CVS Health's leadership during a strategic transition period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:22:09.235289+00:00","company_name":"CVS HEALTH Corp","ticker":"CVS","filing_date":"2026-08-17"},{"id":30174,"accession_number":"0001193125-26-354096","item_number":"7.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces both a board appointment (Teresa Heitsenrether effective November 18, 2026) and a board departure (Larry Robbins, effective August 13, 2026). While the taxonomy includes separate categories for exec_appointment and exec_departure, this filing centers on board composition changes rather than officer/executive management roles. The appointment of a director with significant technology and data analytics expertise to a major healthcare company's board is material to investors assessing governance and strategic direction, but the event is most accurately classified as governance_other since it involves simultaneous appointment and departure at the board level rather than a single executive officer transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:22:09.235289+00:00","company_name":"CVS HEALTH Corp","ticker":"CVS","filing_date":"2026-08-17"}]}